U.S. CDC Endorses Protein-Based COVID-19 Vaccine
The U.S. CDC Director Rochelle P. Walensky, M.D., M.P.H., announced her endorsement of the Advisory Committee on Immunization Practices (ACIP) recommendation that Novavax's COVID-19 Vaccine, Adjuvanted, become available as a primary two-dose series option for most adults.
Novavax's protein-based COVID-19 vaccine will be available in the USA soon. To date, the U.S. government has agreed to order 3.2 million doses of the Novavax vaccine under these existing agreements.
Novavax's vaccine is currently authorized in about forty countries under the names of Nuvaxovid™ and CovoVax™.
The following quote is attributable to Dr. Walensky on July 19, 2022: "Today, we have expanded the options available to adults in the U.S. by recommending another safe and effective COVID-19 vaccine."
"If you have been waiting for a COVID-19 vaccine built on a different technology than previously available, now is the time to join the millions of vaccinated Americans."
The vaccine was created using Novavax's recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax's patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
Vaccines using protein subunits have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the USA include those to protect against influenza and whooping cough (acellular pertussis).
According to a U.S. White House statement also issued on July 19, 2022, 'The science and data are clear: vaccines continue to protect people from serious illness, hospitalizations, and death.'
As of July 20, 2022, about 21% of U.S. residents had not received any COVID-19 vaccination, and only 67% had completed a two-dose primary series.
PrecisionVaccinations publishes fact-checked, research-based vaccine news curated for mobile readership.